Black Rock Inc. Reata Pharmaceuticals Inc Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$79.22 - $105.37 $26.1 Million - $34.7 Million	329,021 Added 14.89%	2,538,770 $259 Million
Q1 2023 May 12, 2023	SELL	$30.85 - $93.17 $9.01 Million - $27.2 Million	-292,209 Reduced 11.68%	2,209,749 $201 Million
Q4 2022 Feb 13, 2023	BUY	$22.15 - $42.11 $145,902 - $277,378	6,587 Added 0.26%	2,501,958 $95 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $6.52 Million - $12.3 Million	335,724 Added 15.55%	2,495,371 $62.7 Million
Q2 2022 Aug 12, 2022	BUY	$20.71 - $36.5 $1.74 Million - $3.06 Million	83,887 Added 4.04%	2,159,647 $65.6 Million
Q1 2022 May 12, 2022	SELL	$24.12 - $39.6 $923,554 - $1.52 Million	-38,290 Reduced 1.81%	2,075,760 $68 Million
Q4 2021 Feb 10, 2022	SELL	$25.61 - $110.96 $170,869 - $740,325	-6,672 Reduced 0.31%	2,114,050 $55.7 Million
Q3 2021 Nov 09, 2021	SELL	$100.0 - $143.02 $1.5 Million - $2.15 Million	-15,049 Reduced 0.7%	2,120,722 $213 Million
Q2 2021 Aug 11, 2021	BUY	$78.27 - $151.29 $167 Million - $323 Million	2,135,771 New	2,135,771 $302 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.